Circulating tumor cell isolation and diagnostics: Toward routine clinical use

Cancer Research

Volumn 71, Issue 18, 2011, Pages 5955-5960

  Van De Stolpe, Anja ^a   Pantel, Klaus ^b   Sleijfer, Stefan ^c   Terstappen, Leon W ^d   Den Toonder, Jaap M J ^a  

^a PHILIPS RESEARCH LABORATORIES   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CD45 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CELL ASSAY; CELL DIVISION; CELL HETEROGENEITY; CELL ISOLATION; CIRCULATING TUMOR CELL; COLON CANCER; CONFERENCE PAPER; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MICROMETASTASIS; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR GROWTH;

HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 80052808533     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1254     Document Type: Conference Paper

References (33)

1. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.
2. Bianchini D, Zivi A, Sandhu S, de Bono JS. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 2010;21 Suppl 7:vii43-55.
3. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004;101:9393-8. (Pubitemid 38812885)
4. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010;124:403-12.
5. Attard G, Swennenhuis JF, Olmos D, Reid AHM, Vickers E, A'Hern R, et al. Characterization of ERG, AR and PTEN status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
6. Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA, et al. Circulating tumour cell detection on its way to routine diagnostics implementation? Eur J Cancer 2007;43:2645-50.
7. Pantel K. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010;16:398-406.
8. den Toonder JMJ. Circulating tumor cells: the grand challenge. Lab Chip 2011;11:375-7.
9. Coumans F, Doggen CJM, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+CD45-CK+ but not EpCAM+CD45+CK+ objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010;21:1851-7.
10. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61-6.
11. Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011;127:33-41.
12. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-63.
13. Tan SJ, Lakshmi RL, Chen PF, Lim WT, Yobas L, Lim CT. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron 2010;26:1701-5.
14. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang X H.-F, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-26.
15. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumor evolution inferred by single cell sequencing. Nature 2011;472:90-4.
16. Ligthart SJ, Coumans FAW, Attard G, Mulick Cassidy A, de Bono JS, Terstappen LW. Automated identification of circulating tumor cells. Philadelphia (PA): AACR; 2011. Abstract nr 4683.
17. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011;17:667-77.
18. Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med 2009;133:1468-71.
19. Philips Digital Pathology. Available from: http://www.research.philips. com/initiatives/digitalpathology.
20. Larsson C, Grundberg I, Söderberg O, Nilsson M. In situ detection and genotyping of individual mRNA molecules. Nat Methods 2010;7:395-7.
21. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009;118:455-68.
22. Balasubramanian P, Yang L, Lang JC, Jatana KR, Schuller D, Agrawal A, et al. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm 2009;6:1402-08.
23. ImageStream flow cytometer. Available from: https://www.amnis.com/papers. html.
24. Talasaz AH, Powell AA, Huber DE, Berbe JG, Roh K-H, Yu W, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970-5.
25. Stott SL, Hsu C-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
26. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010;10:27-9.
27. Saliba A-E, Saias L, Psycharia E, Minc N, Simon D, Bidard F-C, et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A 2010;107:14524-9.
28. Stakenborg T, Liu C, Henry O, O'Sullivan CK, Fermer C, Roeser T, et al. Lab-on-a-chip for the isolation and characterization of circulating tumor cells. Conf Proc IEEE Eng Med Biol Soc 2010;2010:292-4.
29. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, et al. ISET, isolation by size of epithelial tumor cells: a new method for isolation, immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156:1-7.
30. Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 2011;13:203-13.
31. Gascoyne PR, Noshari J, Anderson TJ, Becker FF. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 2009;30:1-11.
32. Holmes D, Pettigrew D, Reccius CH, Gwyer JD, van Berkel C, Holloway J, et al. Leukocyte analysis and differentiation using high speed microfluidic single cell impedance cytometry. Lab Chip 2009;9:2881-9.
33. Alix-Panabières C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 2005;51:1538-41. (Pubitemid 41060898)